Abstract

Tuberculosis (TB) is one of the oldest infectious diseases that affected humankind and remains one of the world’s deadliest communicable diseases that could be considered as global emergency, but the discovery and development of isoniazid (INH) in the 1950s paved the way to an effective single and/or combined first-line anti-TB therapy. However, administration of INH induces severe hepatic toxicity in some patients. Previously, we establish a rat model of INH hepatotoxicity utilizing the inflammatory stress theory, in which bacterial lipopolysaccharide (LPS) potentially enhanced INH toxicity. These enhancing activities ranged between augmenting the inflammatory stress, oxidative stress, alteration of bile acid homeostasis, and CYP2E1 over-expression. Although pre-treatment with dexamethasone (DEX) helped overcome both inflammatory and oxidative stress which ended-up in alleviation of LPS augmenting effects, but still minor toxicities were being detected, alongside with CYP2E1 over expression. This finding positively indicated the corner-stone role played by CYP2E1 in the pathogenesis of INH/LPS-induced liver damage. Therefore, we examined whether INH/LPS co-treatment with CYP2E1 inhibitor diallyl sulfide (DAS) and DEX can protect against the INH/LPS-induced hepatotoxicity. Our results showed that pre-administration of both DAS and DEX caused significant reduction in serum TBA, TBil, and gamma-glutamyl transferase levels. Furthermore, the histopathological analysis showed that DAS and DEX could effectively reverse the liver lesions seen following INH/LPS treatment and protect against hepatic steatosis as indicated by absence of lipid accumulation. Pre-treatment with DAS alone could not completely block the CYP2E1 protein expression following INH/LPS treatment, as appeared in the immunoblotting and immunohistochemistry results. This is probably due to the fact that the combined enhancement activities of both INH and LPS on CYP2E1 protein expression levels might resist the blocking probabilities of DAS. In the meantime, addition of DEX to the DAS/INH/LPS combination caused a significant reduction in CYP2E1 protein expression as revealed by the immunoblotting and fading coloration in immunohistochemistry results. Thus, addition of DEX and DAS together caused strong protection against INH/LPS-induced hepatic damage. These findings reveal the potential therapeutic value of combining DAS and DEX with INH in TB management for reducing the potential risk and incidences of hepatotoxicity.

Highlights

  • Tuberculosis (TB) existed throughout human history as an infectious deadliest communicable diseases that affected humankind, with still high mortality and disease burden (Ramappa and Aithal, 2013; Caulfield and Wengenack, 2016; Cervantes, 2016)

  • Serum total bile acids (TBA), total bilirubin (TBil), and γGGT were significantly raised (P < 0.001) following INH/LPS treatment, whereas pre-addition of diallyl sulfide (DAS) alone caused insignificant changes in their levels compared to both control and INH/LPS groups, while pre-administration of both DAS and DEX caused marked reduction in their serum levels, which were almost indifferent from the control group levels (Figures 1C,D)

  • Data were represented as mean ± SD, n = 7 for each bar. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 versus control, #P < 0.05, ##P < 0.01, ###P < 0.001 versus INH/LPS or DAS/INH/LPS combination, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was set as reference control gene. (G) Immunoblotting analysis of different targeted proteins following INH/LPS with or without DAS and DEX treatment, β-actin considered as loading control

Read more

Summary

Introduction

Tuberculosis (TB) existed throughout human history as an infectious deadliest communicable diseases that affected humankind, with still high mortality and disease burden (Ramappa and Aithal, 2013; Caulfield and Wengenack, 2016; Cervantes, 2016). INH-induced hepatotoxicity is a serious problem and mainly linked with therapy interruption and changes in treatment regimen during the TB management course (Tostmann et al, 2008; Khalili et al, 2009). The exact incidence of INH-induced liver injury is difficult to estimate retrospectively, mainly due to notorious cases underreporting and the contribution of comedications. In their recent comprehensive prospective studies that included patients from different countries, many researchers have revealed that incidence of serious INH-induced liver has been in the range of 1–3% of treated (exposed) patients (Steele et al, 1991; Bjornsson et al, 2013; Shu et al, 2013)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call